Page last updated: 2024-09-02

ecteinascidin 743 and Cystadenocarcinoma, Serous

ecteinascidin 743 has been researched along with Cystadenocarcinoma, Serous in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aracil, M; Badri, N; Galmarini, CM; Herzog, TJ; Kaye, SB; Monk, BJ; Nieto, A; Parekh, TV; Poveda, A; Tanović, A	1

Trials

1 trial(s) available for ecteinascidin 743 and Cystadenocarcinoma, Serous

Article	Year
Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial. Gynecologic oncology, 2014, Volume: 132, Issue:1 Topics: Biomarkers; Cell Cycle Proteins; Cystadenocarcinoma, Serous; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nuclear Proteins; Ovarian Neoplasms; Polyethylene Glycols; Proportional Hazards Models; Retrospective Studies; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome	2014

Article

Year

Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial.

Gynecologic oncology, 2014, Volume: 132, Issue:1

Topics: Biomarkers; Cell Cycle Proteins; Cystadenocarcinoma, Serous; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nuclear Proteins; Ovarian Neoplasms; Polyethylene Glycols; Proportional Hazards Models; Retrospective Studies; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome

2014